ipharmacenter Consulting services

BEST SELLING CANCER DRUGS | TOP ONCOLOGY DRUGS | 2025 Rank Brand Revenues 1 Keytruda $ 23.3 billion 2 Darzalex $ 10.4 billion 3 Opdivo $ 7.4 billion 4 Tagrisso $ 5.4 billion 5 Imfinzi $ 4.3 billion 6 Verzenio $ 4.1 billion 7 Kisqali $ 3.5 billion 8 Tecentriq $ 3.3 billion 9 Ibrance $ 3.0 billion 10 Perjeta $ 2.9 billion In 2025, global oncology revenues continue to be dominated by immune checkpoint inhibitors and targeted therapies, with Merck’s PD‑1 inhibitor Keytruda far ah

Roche recently disclosed promising findings from the phase III lidERA Breast Cancer trial, where their experimental oral drug, giredestrant, showed a significant improvement in invasive disease-free survival compared to standard endocrine therapies. This study involved over 4,100 patients diagnosed with early-stage breast cancer characterized by oestrogen receptor-positive (ER+), HER2-negative tumors. The trial’s interim analysis revealed that giredestrant not only met but su

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab) administered subcutaneously in combination with rituximab and lenalidomide (EPKINLY + R2) for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least one prior systemic therapy. This newly approved regimen is the first and only bispecific antibody combination therapy available for this patient population. The approval was granted base

Merck's Keytruda (pembrolizumab) Achieves Primary Goal of Event-Free Survival (EFS) in Perioperative Treatment for Patients with Resected...

Merck has announced the discontinuation of its Phase 3 KeyVibe-008 trial, which was investigating a fixed-dose combination of...

April 08, 2024 Krazati plus cetuximab showed improvement in objective response rate in patients with KRASG12C-mutated CRC Mirati...

January 09, 2024 FDA raised concerns regarding manufacturing facility of Astellas' zolbetuximab but had no comments on efficacy and...

November 01, 2023 Keytruda Demonstrated Improvement in Overall Survival in Patients with Renal Cell Carcinoma Merck has recently unveiled...

BeiGene, a prominent global biotechnology company, has recently shared positive regulatory updates regarding its innovative cancer...

The Phase 3 MARIPOSA-2 study has achieved significant breakthroughs in treating EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC),...

BMS announced that Breyanzi (lisocabtagene maraleucel) met the primary endpoint of the overall response rate in two types of...

Janssen and AbbVie announced they would withdraw mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) applications in the US....

Novartis presented the positive results of the NATALEE study, demonstrating the benefit of Kisqali (ribociclib) plus endocrine therapy in...

Astellas and Pfizer announced positive topline results from the Phase 3 EMBARK trial, which evaluated the effectiveness of Xtandi...

Keytruda met the primary endpoint in the Phase 3 KEYNOTE-859 trial in patients with HER2-negative gastric cancer. Merck announced that...

FDA accepted the NDA of GSK's momelotinib for myelofibrosis GSK announced that the U.S. Food and Drug Administration accepted the new...

October 17, 2022 Bayer expands its breast cancer portfolio by expanding the OASIS program of elinzanetant. Bayer announced that it had...